Defencath FDA Approval Status
Last updated by Judith Stewart, BPharm on Dec 3, 2020.
FDA Approved: No
Brand name: Defencath
Generic name: taurolidine
Company: CorMedix Inc.
Treatment for: Prevention of Catheter Related Blood Stream Infections (CRBSI)
Defencath (taurolidine) is a synthetic broad-spectrum antimicrobial and antifungal in development for use as a catheter lock solution in hemodialysis patients for the prevention of catheter related blood stream infections (CRBSI).
Development Timeline for Defencath
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.